LP
DNA icon

LMR Partners’s Ginkgo Bioworks DNA Stock Holding History

LMR Partners’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,883
Closed -$195K – 1193
2023
Q4 		$195K Hold
2,883
– – ﹤0.01% 734
2023
Q3 		$209K Sell
2,883
-5,382
-65% -$430K ﹤0.01% 636
2023
Q2 		$615K Buy
+8,265
New +$489K 0.01% 473

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LMR Partners's DNA Position: Q1 2022 in Review

LMR Partners sold out of Ginkgo Bioworks (DNA) in Q1 2022, closing a stake of 3,517 shares — an estimated $1.17M sold.

LMR Partners first reported a position in DNA in Q4 2021 and held it in 1 quarter. The position peaked at $1.17M in Q4 2021. 190 funds tracked by Wall St. Rank hold DNA as of Q1 2022.

  • LMR Partners reported no remaining Ginkgo Bioworks position as of Q1 2022 after selling out during the quarter.
  • LMR Partners sold 3,517 Ginkgo Bioworks shares in Q1 2022, an estimated $1.17M.
  • LMR Partners first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 1 quarter.
  • LMR Partners's Ginkgo Bioworks position peaked at $1.17M in Q4 2021.
  • 190 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2022.

Based on LMR Partners's 13F filing for Q1 2022, filed 16 May 2022.